Becton, Dickinson and Company (NYSE:BDX) Now Covered by Analysts at Evercore

Key Points

• Evercore initiated coverage of Becton, Dickinson & Company with an "outperform" rating and a $180 price target, implying roughly a 20% upside from the stock's current level.
• The analyst consensus is mixed—seven Buy and nine Hold ratings—with an average rating of "Hold" and an average price target of $188.43; several firms have set higher targets (e.g., Stifel $215, Barclays $202).
• Recent results and moves: BDX reported $2.91 EPS (beat) but missed revenue expectations, set FY2026 guidance of $12.35–$12.65 EPS, trades near $149.97 with a $42.7B market cap, announced a $10M share repurchase program, and insiders have recently sold shares.

Stock analysts at Evercore initiated coverage on shares of Becton, Dickinson and Company (NYSE:BDX - Get Free Report) in a report issued on Monday. The brokerage set an "outperform" rating and a $180.00 price target on the medical instruments supplier's stock. Evercore's price objective would suggest a potential upside of 20.02% from the stock's current price.

Several other equities analysts also recently issued reports on BDX. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a research note on Tuesday, April 14th. Barclays started coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They set an "overweight" rating and a $202.00 price target on the stock. Stifel Nicolaus increased their price target on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a "buy" rating in a research note on Wednesday, January 7th. Bank of America increased their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a "neutral" rating in a research note on Monday, January 5th. Finally, TD Cowen increased their price target on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a "hold" rating in a research note on Wednesday, February 11th. Seven investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has an average rating of "Hold" and an average price target of $188.43.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX traded up $0.66 on Monday, hitting $149.97. The company's stock had a trading volume of 89,049 shares, compared to its average volume of 2,751,457. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a market capitalization of $42.70 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 10.65 and a beta of 0.22. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The stock has a 50 day moving average of $160.69 and a 200-day moving average of $181.92.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. The company had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company's revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.52 EPS for the current year.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase program on Tuesday, January 27th that allows the company to repurchase $10.00 million in shares. This repurchase authorization allows the medical instruments supplier to reacquire up to 0% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Insider Activity

In other news, Director Bertram L. Scott sold 953 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director owned 36,763 shares of the company's stock, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 1,102 shares of company stock valued at $198,909 over the last ninety days. 0.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several large investors have recently made changes to their positions in the business. Activest Wealth Management grew its holdings in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 97 shares in the last quarter. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $25,000. Steph & Co. grew its holdings in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 65 shares in the last quarter. SHP Wealth Management acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at $26,000. Finally, Prosperity Bancshares Inc acquired a new stake in Becton, Dickinson and Company during the 4th quarter valued at $29,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.